Novocure receives NCCN clinical practice recommendation
Novocure announced that the National Comprehensive Cancer Network, or NCCN, has updated its clinical practice guidelines to recommend Optune in combination with temozolomide as a category 1 treatment for newly diagnosed glioblastoma, or GBM, in its globally recognized Clinical Practice Guidelines in Oncology for Central Nervous System Cancers. NCCN panel members designated alternating electric field therapy, or Optune, as a Category 1 treatment recommendation for patients with newly diagnosed GBM in conjunction with temozolomide after maximal safe resection and completion of radiation therapy in patients with newly diagnosed GBM. The updated recommendation follows the publication of Novocure's EF-14 phase 3 pivotal trial five-year survival results in the Journal of the American Medical Association.The EF-14 five-year survival results demonstrated Optune plus temozolomide significantly improved survival outcomes in patients with newly diagnosed GBM compared to temozolomide alone. A category 1 recommendation indicates, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.